Snapshot

PCSK9 shot: 62% LDL reduction

From Moonshots with Peter Diamandis · Jun 6, 2026

Health & Fitness

Anthropic Files $965B IPO, Trump Signs AI Executive Order, … · Jun 6, 2026

A single-infusion gene-editing therapy (VRRV-102) targeting the PCSK9 gene reduced LDL cholesterol by 62% and PCSK9 protein levels by 88% in a Phase 1 trial.